company background image
3010

Shanghai Labway Clinical Laboratory SZSE:301060 Stock Report

Last Price

CN¥21.12

Market Cap

CN¥8.5b

7D

0%

1Y

12.5%

Updated

07 Oct, 2022

Data

Company Financials
301060 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends2/6

301060 Stock Overview

Shanghai Labway Clinical Laboratory Co., Ltd.

Shanghai Labway Clinical Laboratory Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Labway Clinical Laboratory
Historical stock prices
Current Share PriceCN¥21.12
52 Week HighCN¥61.20
52 Week LowCN¥17.91
Beta0
1 Month Change-27.55%
3 Month Change-42.53%
1 Year Change12.52%
3 Year Changen/a
5 Year Changen/a
Change since IPO15.60%

Recent News & Updates

Shareholder Returns

301060CN HealthcareCN Market
7D0%-0.3%-1.1%
1Y12.5%-23.7%-19.2%

Return vs Industry: 301060 exceeded the CN Healthcare industry which returned -23.7% over the past year.

Return vs Market: 301060 exceeded the CN Market which returned -19.2% over the past year.

Price Volatility

Is 301060's price volatile compared to industry and market?
301060 volatility
301060 Average Weekly Movement6.7%
Healthcare Industry Average Movement5.1%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.8%

Stable Share Price: 301060 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 301060's weekly volatility has decreased from 13% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19931,522Weixiong Zenghttps://www.labway.cn

Shanghai Labway Clinical Laboratory Co., Ltd. offers sales services for in vitro diagnostic products; and medical laboratory services. Shanghai Labway Clinical Laboratory Co., Ltd.

Shanghai Labway Clinical Laboratory Fundamentals Summary

How do Shanghai Labway Clinical Laboratory's earnings and revenue compare to its market cap?
301060 fundamental statistics
Market CapCN¥8.46b
Earnings (TTM)CN¥536.21m
Revenue (TTM)CN¥3.07b

15.8x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
301060 income statement (TTM)
RevenueCN¥3.07b
Cost of RevenueCN¥1.73b
Gross ProfitCN¥1.34b
Other ExpensesCN¥805.26m
EarningsCN¥536.21m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.34
Gross Margin43.73%
Net Profit Margin17.48%
Debt/Equity Ratio5.5%

How did 301060 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

21%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 301060 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301060?

Other financial metrics that can be useful for relative valuation.

301060 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA10.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 301060's PE Ratio compare to its peers?

301060 PE Ratio vs Peers
The above table shows the PE ratio for 301060 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average49.8x
000950 C.Q. Pharmaceutical Holding
8.6xn/aCN¥8.4b
600211 Tibet Rhodiola Pharmaceutical Holding
47.5xn/aCN¥8.2b
000078 Shenzhen Neptunus Bioengineering
133xn/aCN¥8.9b
600713 NanJing Pharmaceutical
10.3xn/aCN¥6.4b
301060 Shanghai Labway Clinical Laboratory
15.8xn/aCN¥8.5b

Price-To-Earnings vs Peers: 301060 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the peer average (49.8x).


Price to Earnings Ratio vs Industry

How does 301060's PE Ratio compare vs other companies in the CN Healthcare Industry?

Price-To-Earnings vs Industry: 301060 is good value based on its Price-To-Earnings Ratio (15.8x) compared to the CN Healthcare industry average (21x)


Price to Earnings Ratio vs Fair Ratio

What is 301060's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301060 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301060's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 301060 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301060 (CN¥21.12) is trading above our estimate of fair value (CN¥7.57)

Significantly Below Fair Value: 301060 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Shanghai Labway Clinical Laboratory forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


28.4%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Labway Clinical Laboratory has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Shanghai Labway Clinical Laboratory performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


36.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 301060 has a high level of non-cash earnings.

Growing Profit Margin: 301060's current net profit margins (17.5%) are higher than last year (10.7%).


Past Earnings Growth Analysis

Earnings Trend: 301060's earnings have grown significantly by 36.9% per year over the past 5 years.

Accelerating Growth: 301060's earnings growth over the past year (231.6%) exceeds its 5-year average (36.9% per year).

Earnings vs Industry: 301060 earnings growth over the past year (231.6%) exceeded the Healthcare industry -2.5%.


Return on Equity

High ROE: 301060's Return on Equity (32.6%) is considered high.


Discover strong past performing companies

Financial Health

How is Shanghai Labway Clinical Laboratory's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 301060's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥1.0B).

Long Term Liabilities: 301060's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥54.7M).


Debt to Equity History and Analysis

Debt Level: 301060 has more cash than its total debt.

Reducing Debt: 301060's debt to equity ratio has reduced from 7.3% to 5.5% over the past 5 years.

Debt Coverage: 301060's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 301060 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Shanghai Labway Clinical Laboratory current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.42%

Current Dividend Yield

Dividend Yield vs Market

Shanghai Labway Clinical Laboratory Dividend Yield vs Market
How does Shanghai Labway Clinical Laboratory dividend yield compare to the market?
SegmentDividend Yield
Company (Shanghai Labway Clinical Laboratory)1.4%
Market Bottom 25% (CN)0.5%
Market Top 25% (CN)2.2%
Industry Average (Healthcare)1.2%
Analyst forecast in 3 Years (Shanghai Labway Clinical Laboratory)n/a

Notable Dividend: 301060's dividend (1.42%) is higher than the bottom 25% of dividend payers in the CN market (0.55%).

High Dividend: 301060's dividend (1.42%) is low compared to the top 25% of dividend payers in the CN market (2.16%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether 301060's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 301060's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (21.1%), 301060's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: 301060 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Weixiong Zeng (54 yo)

no data

Tenure

Mr. Weixiong Zeng serves as Chairman of the Board and General Manager at Shanghai Labway Clinical Laboratory Co., Ltd.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 301060?
Owner TypeNumber of SharesOwnership Percentage
Institutions17,464,5834.4%
Individual Insiders64,267,13716.0%
General Public100,976,26325.2%
Private Companies217,809,01754.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 71.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
37.34%
Shanghai Lanwei Investment Co., Ltd.
149,544,017CN¥3.2b-0.01%no data
13.42%
Weixiong Zeng
53,769,291CN¥1.1b0%no data
10.71%
Heilan Group Co., Ltd.
42,900,000CN¥906.0m0%no data
3.33%
Shanghai Huikun Investment Management Center (Limited Partnership)
13,350,000CN¥282.0m0%no data
3%
Shanghai Bozhi Fangde Investment Center (Limited Partnership)
12,015,000CN¥253.8m0%no data
1.62%
Linjie Sun
6,505,680CN¥137.4m0%no data
1%
Jing Yang
3,992,166CN¥84.3m0%no data
0.14%
UBS Asset Management
547,557CN¥11.6m0%no data
0.079%
Shenyin Wanguo Asset Management (Asia) Limited
316,100CN¥6.7m0%0.09%
0.075%
Ubiquant Investment (Beijing) CO.,LTD.
299,836CN¥6.3m0%1.68%
0.055%
CITIC Securities Company Limited, Asset Management Arm
221,362CN¥4.7m0%0.01%
0.043%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
171,518CN¥3.6m0%no data
0.035%
Huatai Securities (Shanghai) Asset Management Co., Ltd.
141,874CN¥3.0m-66.23%0.02%
0.029%
China Southern Asset Management Co., Ltd.
116,703CN¥2.5m0%no data
0.029%
Barclays PLC Private Banking & Investment Banking Investment
114,600CN¥2.4m0%no data
0.027%
ICBC Credit Suisse Asset Management Co., Ltd.
110,003CN¥2.3m0%no data
0.018%
GF Fund Management Co., Ltd.
72,290CN¥1.5m0%no data
0.017%
Guotai Asset Management Co., Ltd.
68,089CN¥1.4m0%no data
0.016%
Bosera Asset Management Co., Ltd.
62,807CN¥1.3m0%no data
0.014%
Harvest Fund Management Co., Ltd.
54,190CN¥1.1m0%no data
0.011%
E Fund Management Co., Ltd.
43,774CN¥924.5k-48%no data
0.011%
Invesco Great Wall Fund Management Co. Ltd
42,264CN¥892.6k0%no data
0.0083%
Huashang Fund Management Company Ltd.
33,116CN¥699.4k0%no data
0.0078%
Wanjia Asset Management Co., Ltd.
31,110CN¥657.0k0%no data
0.0076%
Galaxy Asset Management Company Limited
30,522CN¥644.6k0%no data

Company Information

Shanghai Labway Clinical Laboratory Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Labway Clinical Laboratory Co., Ltd.
  • Ticker: 301060
  • Exchange: SZSE
  • Founded: 1993
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: CN¥8.459b
  • Shares outstanding: 400.52m
  • Website: https://www.labway.cn

Number of Employees


Location

  • Shanghai Labway Clinical Laboratory Co., Ltd.
  • Building 1, Lane 268
  • 5th Floor
  • Shanghai
  • 200335
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
301060SZSE (Shenzhen Stock Exchange)YesDomestic SharesCNCNYSep 2021
301060XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect)YesDomestic SharesCNCNYSep 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/07 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.